Literature DB >> 15519473

High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy.

Giovanna Branca1, Teresa Spanu, Giovanni Cammarota, Anna Maria Schito, Antonio Gasbarrini, Giovanni Battista Gasbarrini, Giovanni Fadda.   

Abstract

Current treatment for Helicobacter pylori infections generally includes two or more antimicrobials (amoxicillin, clarithromycin, nitroimidazoles, tetracycline, etc.), but treatment fails in 10-20% of all cases, often because of drug resistance. Levofloxacin has been proposed as an alternative for these refractory infections. We examined 67 H. pylori isolates from patients unsuccessfully treated with amoxicillin, clarithromycin, metronidazole and levofloxacin. Minimum inhibitory concentrations determined with the epsilometer test revealed clarithromycin and metronidazole resistance in 91 and 82.1% of the isolates, respectively; 52 (77.6%) were resistant to both drugs. All 67 isolates were susceptible to amoxicillin and tetracycline. Fifty-two isolates had levofloxacin MICs of 0.01-2 mg/l; the remaining 15 (22.4%), all clarithromycin- and metronidazole-resistant, had MICs >/= 8 mg/l. Levofloxacin may be an option for refractory H. pylori infections, but the choice should be based on in vitro susceptibility data, and physicians should consider local resistance patterns when treating these infections empirically.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519473     DOI: 10.1016/j.ijantimicag.2004.02.032

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

Review 1.  Severe and refractory peptic ulcer disease: the diagnostic dilemma: case report and comprehensive review.

Authors:  James L Guzzo; Mona Duncan; Barbara L Bass; Grant V Bochicchio; Lena M Napolitano
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

2.  Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai.

Authors:  Qin-Juan Sun; Xiao Liang; Qing Zheng; Wei-Qi Gu; Wen-Zhong Liu; Shu-Dong Xiao; Hong Lu
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

3.  Quinolone resistance in Helicobacter pylori isolates in Germany.

Authors:  Erik Glocker; Hans-Peter Stueger; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Quadruple therapy for eradication of Helicobacter pylori.

Authors:  Hai-Jun Ma; Jin-Liang Wang
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 5.  Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.

Authors:  Alexander A Nijevitch; Bulat Idrisov; Elsa N Akhmadeeva; David Y Graham
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.